News | February 27, 2014

China Announces Claim Coverage Electrode-Based Ablation Balloon to Treat Atrial Fibrillation

Ablation Systems Balloon Atrial Fibrillation Therapies EP Lab Apama Shifamed

February 27, 2014 — Apama Medical is a privately held medical device company formed by Shifamed's medical incubator. It received Chinese notice of allowance for claims covering their low profile electrode assembly that enables the attachment of flexible electrodes to an ablation balloon for energy delivery and monitoring. The Chinese patent will complement an existing patent (U.S. Patent No. 8,295,902) giving Apama broad claim coverage for electrode-based ablation balloons in the United States and China for the treatment of atrial fibrillation (AF). Utilizing this patented electrode technology enables Apama to design an ablation catheter that performs a full pulmonary vein (PV) ablation and rotor ablation in a single-shot.

The global electrophysiology (EP) mapping and ablation market is estimated to reach $4.3 billion in 2017 and is the fastest growing cardiac rhythm management market segment. Worldwide catheter based AF ablation is estimated to grow from 180,000 procedures in 2009 up to 827,000 procedures by 2017. Fundamental barriers to adoption of AF ablation procedures have been attributed to technical complexity and length of procedure time. As a result, there is a large underserved market.

For more information: www.shifamed.com

Related Content

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve